Opko Health (OPK) Research & Development (2010 - 2026)

Opko Health (OPK) has 17 years of Research & Development data on file, last reported at $33.2 million in Q2 2026.

• Quarterly Research & Development rose 9.31% year-over-year to $33.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $125.2 million (down 31.2% YoY) and the FY2025 annual result came in at $124.0 million, up 17.89% from the prior year.
• Research & Development improved to $33.2 million in Q2 2026, from $29.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $74.8 million in Q3 2024 to a low of $17.3 million in Q2 2022.
• A 5-year average of $29.0 million and a median of $29.2 million in 2026 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development soared 284.82% — and 2025, when it sank 59.78%.
• Tracing OPK's Research & Development over 5 years: stood at $19.5 million in 2022, then fell by 0.69% to $19.4 million in 2023, then surged by 285.63% to $74.8 million in 2024, then slumped by 56.18% to $32.8 million in 2025, then increased by 1.2% to $33.2 million in 2026.
• The last three Research & Development figures came in at $33.2 million (Q2 2026), $29.2 million (Q1 2026), and $32.8 million (Q4 2025), per Business Quant data.